5Joint Task Force on the Management of Valvular Heart Disease ofthe European Society of Cardiology ( ESC) ; European Associationfor Cardio - Thoracic Surgery ( EACTS) , Vahanian A, et al.Guidelines on the management of valvular heart disease ( version2012) [J]. Eur Heart J, 2012,33(19) : 2451-2496.
6Biswas I,Mathew PJ, Singh RS, et al. Evaluation of closed-loopanesthesia delivery for propofol anesthesia in pediatric cardiac sur-gery [J]. Paediatr Anaesth, 2013, 23( 12) : 1145-1152.
7Yang XY,Zhou ZB, Yang et al. Hemodynamic responses dur-ing induction : comparison of Marsh and Schnider pharmacokineticmodels [ J]. Int J Clin Pharmacol Ther, 2015, 53(1) :32-40.
8Viterbo JF, Lourenco AP, Leite-Moreira AF, et al. Prospectiverandomised comparison of Marsh and Schnider pharmacokineticmodels for propofol during induction of anaesthesia in elective car-diac surgery[ J]. Eur J Anaesthesiol, 2012, 29(10) : 477-483.
9Miyoshi H, Kusunoki S, Kawamoto M. Total intravenous anesthe-sia for a patient with cardiac sarcoidosis associated with left ven-tricular dysfunction using remifentanil and propofol [ J ] . Masui,2010, 59(6): 715-718.
10Benetti F, Mariani MA, Sani G, et al. Video-assisted minimallyinvasive coronary operations without cardiopulmonary bypass : amulticenter study [ J]. J Thorac Cardiovasc Surg, 1996,112(6):1478-1484.
